Clinical ink is pleased to announce the launch of EDCXtra?, an innovative Electronic Data Capture (EDC) system.?EDCXtra is based on the company’s best in class direct data capture (DDC)/eSource platform, which has evolved over 17 years, and resulted in multiple FDA approvals.?EDCXtra incorporates all existing DDC functionality into a single web-based application which includes Clinical ink’s industry leading electronic Clinical Outcome Assessments (eCOAs) and eConsent solutions, providing a comprehensive, all-in-one GCP compliant platform. ? Read more about EDCXtra in our press release here: https://lnkd.in/ehEKmxi6
Right you are, Ed. And site optionality equals site empowerment; allowing sites to choose the data capture process that fits them rather than having that dictated by the sponsor. This new offering also allows sponsors to ease into DDC, creating a blend of DDC and EDC sites and seeing for themselves which approach works best. Flexible data capture is difficult to create, but a boon for both sites and sponsors. Congrats to the CI team!
This is great. Another creative product from Clinical ink that will drive quality and accelerate drug development.
Very promising!
Pharma Technology Executive and Investor
5 个月I used to call this 'Site Optionality' - let the site decide how to best capture the data to fit their workflows. Some will choose eSource (DDC) to eliminate secondary data entry and improve protocol compliance; others will opt for the minimum EDC data entry fields. I know how hard this is to pull off both technically and from a User Experience. Great job CI team!